Evidence map›Paper›PMID 31856199›Full record

ArticlePLoS neglected tropical diseases2019

Premature deaths by visceral leishmaniasis in Brazil investigated through a cohort study: A challenging opportunity?

Ana Nilce S Maia-Elkhoury, Gustavo Adolfo Sierra Romero, Samantha Y O B Valadas, Marcia L Sousa-Gomes, José Angelo Lauletta Lindoso, Elisa Cupolillo, Jose Antonio Ruiz-Postigo, Daniel Argaw, Manuel J Sanchez-Vazquez

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Ana Nilce S Maia-ElkhouryCommunicable Diseases and Environmental Determinants of Health (CDE), Neglected, Tropical and Vector Borne Diseases (VT), Pan American Health Organization/ World Health Organization (PAHO/WHO), Duque de Caxias, Rio de Janeiro, Brazil.ORCID 0000-0001-5369-5860
Gustavo Adolfo Sierra RomeroCenter for Tropical Medicine, Faculty of Medicine, University of Brasilia (UNB) Brasília, Distrito Federal, Brazil.
Samantha Y O B ValadasCommunicable Diseases and Environmental Determinants of Health (CDE), Neglected, Tropical and Vector Borne Diseases (VT), Pan American Health Organization/ World Health Organization (PAHO/WHO), Duque de Caxias, Rio de Janeiro, Brazil.
Marcia L Sousa-GomesSecretary of Health Surveillance (SVS), Ministry of Health, Brasilia, Distrito Federal, Brazil.
José Angelo Lauletta LindosoInstitute of Infectology Emilio Ribas and Institute of Tropical Medicine from University of São Paulo, São Paulo, Brazil.
Elisa CupolilloOswaldo Cruz Institute (IOC) Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.ORCID 0000-0002-0620-3250
Jose Antonio Ruiz-PostigoDepartment of Neglected Tropical Diseases (HTM/NTD/IDM), World Health Organization (WHO), Geneva, Switzerland.
Daniel ArgawDepartment of Neglected Tropical Diseases (HTM/NTD/IDM), World Health Organization (WHO), Geneva, Switzerland.
Manuel J Sanchez-VazquezPan-American Foot-and-Mouth Disease Center-PANAFTOSA/PAHO, Duque de Caxias, Rio de Janeiro, Brazil.
Pan American Health Organization (Brasil) · BRWorld Health Organization · CHCentro Panamericano de Fiebre Aftosa · BRFundação Oswaldo Cruz · BRMinistério da Saúde · BRUniversidade de Brasília · BRUniversidade de São Paulo · BR

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundVisceral Leishmaniasis (VL) is the most severe form of leishmaniasis because it can lead to death. In the Americas, 96% of cases are in Brazil, and despite efforts, the fatality rate has increased in the past years. We analyzed deaths associated to VL in Brazil and investigated the factors that could influence on the timeliness of fatal outcome with emphasis on time (tStoD). METHODOLOGY: The registered deaths by VL were sourced from the Brazilian National Notification System from 2007-2014. Through a retrospective cohort study, univariate and multivariable Cox proportional hazards model analysis were performed and investigated the factors that could influence the time (tStoD). These factors were analyzed through survival models.

resultsOut of the 1,589 reported deaths, the median for onset of the symptoms and the case notification date (tStoN) is 25 days (10-61), and for date of case notification and death (tNotD) is 9 days (4-17). The time (tStoN) to event investigation for HIV non-infected individuals was 1.4 (1.16-1.68) greater than the HIV positive group. At the same time peri-urban and urban area were 0.83 (0.47-1.44) and 1.33 (1.16-1.52), respectively. The explorations revealed apparent differences between the time to event investigation (both for tStoN and tNotD) and the age at the onset of the symptoms. According to the tStoN the rate of notification is 1.73 times greater in patients under 5 years old at the onset of the clinical symptoms compared to older patients.

conclusionVL patients under 5 years old were diagnosed earlier and had shorter survival. It could mean that in younger population, although properly diagnosed, the fatality pattern might be related to the severity of the disease. Main host characteristics were evaluated, and age and co-infections seem to have an impact in the disease progression.

Indexed as

Mortality, PrematureAdolescentAdultAgedAged, 80 and overBrazilChildChild, PreschoolFemaleHumansInfantInfant, NewbornLeishmaniasis, VisceralMaleMiddle AgedRetrospective Studies

Identifiers

PMID31856199
PMCPMC6922316
OpenAlexW2996228100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.